GlassScriptPhysician profile
Lindi Caylin Ciglar
NPI 1558830968
$14,600.35
in general payments reported to CMS, 2019-2025
25 companies · $3,509 in 2025
The $3,509 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,238 · 2022: $1,932 · 2023: $2,727 · 2024: $3,195 · 2025: $3,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,757 · Consulting Fee: $555 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,757.25 |
| Consulting Fee | $555.00 |
| Education | $117.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,076.43 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $1,734.13 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,589.25 | 2021-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,242.81 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,122.38 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $994.96 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $839.00 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $700.44 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $665.98 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $576.12 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $518.15 | 2021-2025 | Qelbree, Qelbree |
| Indivior INC. | $394.51 | 2021-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $350.93 | 2021-2022 | |
| Axsome Therapeutics, INC. | $345.30 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $332.55 | 2021-2025 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $228.74 | 2024 | Xelstrym |
| Noven Therapeutics, LLC | $220.88 | 2023-2025 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $155.80 | 2022-2024 | Jornay Pm |
| Sage Therapeutics, LLC | $142.94 | 2021-2024 | |
| Tris Pharma INC | $108.64 | 2023-2024 | Dyanavel Xr |
| Eisai INC. | $84.95 | 2021 | |
| Corium, LLC | $74.80 | 2021-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $62.75 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.65 | 2024 | |
| Merck Sharp & Dohme LLC | $15.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindi Ciglar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.